Status:
ACTIVE_NOT_RECRUITING
Patient and Caregiver Attitudes and Beliefs Regarding Prescription of Intranasal Naloxone Spray for Opioid Overdose
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Caregiver
Patient
Eligibility:
All Genders
18+ years
Brief Summary
This trial studies the attitudes and beliefs of high risk patients and caregivers regarding the prescription of intranasal naloxone spray for opioid overdose. Knowledge regarding high risk patients' a...
Detailed Description
PRIMARY OBJECTIVE: I. To determine the proportion of high risk patients who perceive receiving a prescription of intranasal naloxone to be beneficial for them. SECONDARY OBJECTIVES: I. To determine...
Eligibility Criteria
Inclusion
- Patients must have been prescribed intranasal naloxone in the past 1 year
- Patients and caregivers must be able to understand, read, write, and speak English
- Patients must have no clinical evidence of cognitive impairment, as determined by the palliative care provider (Memorial Delirium Assessment Scale score of \>= 7)
- Patients must sign an informed consent
- Caregivers may sign an informed consent if available during the visit
- Caregivers may verbally consent over the phone if not present during the visit
- Caregiver must be a friend, significant other or family member
- Caregivers must have no evidence of cognitive impairment, as determined based on orientation questions pertaining to the date, day of the week, time, and place
Exclusion
- PATIENT: Emotional or psychosocial distress as identified by the patient's palliative care
- PATIENT: Participants with Edmonton Symptom Assessment System (ESAS) anxiety score of \> 6
Key Trial Info
Start Date :
July 18 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2026
Estimated Enrollment :
182 Patients enrolled
Trial Details
Trial ID
NCT04129138
Start Date
July 18 2020
End Date
June 30 2026
Last Update
October 14 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
M D Anderson Cancer Center
Houston, Texas, United States, 77030